AGLE NASDAQ
Austin, TX 78746
US
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating human enzyme therapies for rare metabolic diseases. Their leading candidate, pegzilarginase, a recombinant human Arginase 1, is currently in the pivotal Phase III PEACE trial to assess its safety and effectiveness for treating Arginase 1 deficiency. Furthermore, the company is developing AGLE-177, a polyethylene glycol modified enzyme, which is progressing through Phase I/II clinical trials for homocystinuria. Their early-stage pipeline includes AGLE-325 for cystinuria, along with other ongoing research initiatives. Founded in 2013, the company was initially known as Aeglea BioTherapeutics Holdings, LLC, changing its name to Aeglea BioTherapeutics, Inc. in March 2015. It is based in Austin, Texas.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fairmount Funds Mana | J-Other | 406,038 | — | 2023-12-29 |
| Fairmount Funds Mana | J-Other | 3,435,480 | — | 2023-12-29 |
| Burrows Scott L | A-Award | 134,953 | — | 2023-12-22 |
| Fairmount Funds Mana | A-Award | 16,667 | — | 2023-12-07 |
| Fairmount Funds Mana | C-Conversion | 3,435,480 | — | 2023-11-24 |